Chlorotoxin
- Generic Name
- Chlorotoxin
- Drug Type
- Biotech
- CAS Number
- 163515-35-3
- Unique Ingredient Identifier
- 06UV5RFW57
- Background
Chlorotoxin is under investigation in clinical trial NCT00733798 (A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma).
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
Phase 1
Recruiting
- Conditions
- Recurrent GlioblastomaRecurrent WHO Grade III GliomaRecurrent Malignant GliomaRecurrent WHO Grade II Glioma
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT04214392
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma
Phase 1
- Conditions
- Malignant GliomaGlioblastoma MultiformeGBMAstrocytomaOligodendroglioma
- Interventions
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2009-07-17
- Lead Sponsor
- TransMolecular
- Target Recruit Count
- 36
- Registration Number
- NCT00591058
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath